Thomas N. Chase, MD, Joins GT Biopharma, Inc. as an Advisor to…
GT Biopharma, Inc. (OXISD) Welcomes Thomas N. Chase, MD
Search Results
oxis
79 posts
GT Biopharma (OXISD) Announces Development Plan For Non-Opioid Neuropathic Pain Treatment “PainBrake”
LOS ANGELES, CA / ACCESSWIRE / September 11, 2017 / GT Biopharma…
GT Biopharma (OXISD) Hires Former Pfizer CMO/Vice President and Senior Director of Oncology Research as CMO
LOS ANGELES, CA / ACCESSWIRE / September 7, 2017 / GT Biopharma…
GT Biopharma Inc. (OXISD) Announces Reverse Stock Spilt As Part of Planned Merger
GT Biopharma, Inc. Announces Reverse Stock Spilt As Part of Oxis-Georgetown Planned…
GT Biopharma Inc. (OXIS) Executives to Present at Rodman & Renshaw Conference in New York
GT Biopharma (OXIS) Executives to Present at Rodman & Renshaw Conference in…
GT Biopharma Inc. (OXIS) Announces Corporate Update Conference Call
GT Biopharma, Inc. (Oxis) Announces Corporate Update Conference Call With Incoming CEO…
GT Biopharma Inc. (OXIS) Announces Enrollment of Fourth Patient in FDA Phase 2 Trial
GT Biopharma (OXIS) Announces Enrollment of Fourth Patient in FDA Phase 2…
$OXIS Adds New Patients in Phase 1/Phase 2 Clinical Trials
Oxis Adds New Patients in Phase 1/Phase 2 Clinical Trial of Key…
$OXIS Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical Trial
Oxis Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical…
$OXIS Announces Key U.S. Patent Issued for Its Cancer Drug, OXS-1550
OXIS Biotech Announces Key U.S. Patent Issued for Its Cancer Drug, OXS-1550…
